BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11735110)

  • 1. Recombinant factor VIIa (Novoseven) as a hemostatic agent.
    Hedner U
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):43-7. PubMed ID: 11735110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
    Hedner U
    Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of recombinant activated factor VII: an update.
    Hedner U
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing with recombinant factor viia based on current evidence.
    Hedner U
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):35-9. PubMed ID: 14872419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Novo Nordisk's clinical trial programme on NovoSeven.
    Dejgaard A
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S39-41. PubMed ID: 14567535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U
    Curr Opin Hematol; 2007 May; 14(3):225-9. PubMed ID: 17414211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General haemostatic agents--fact or fiction?
    Hedner U
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa (Novoseven) and the safety of treatment.
    Roberts HR
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
    Abshire TC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor treatment: state of the art.
    Shapiro A
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):26-34. PubMed ID: 11735107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor XI deficiency.
    O'connell NM
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):76-81. PubMed ID: 14872426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of recombinant-activated factor VII in neurocritical care.
    Fewel ME; Park P
    Neurocrit Care; 2004; 1(1):19-29. PubMed ID: 16174895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.